Author: Fiona Craig
-
DroneShield, NEO Battery, and BYD: Innovations in a billion-dollar market
Drones are rapidly changing modern warfare. Today, inexpensive aircraft can threaten even expensive military technology, pushing traditional defense systems to their limits. At the same time, the demand for powerful batteries is increasing, as range and operating time could become decisive factors. AI-supported drone defense, high-performance batteries, and new battery technologies are thus at the…
-
Oil Near $100 Viewed as Manageable for U.S. Economy, Capital Economics Says
Crude prices approaching $100 per barrel may not be especially harmful for the U.S. economy, according to research firm Capital Economics, which notes that the country’s position as a modest net exporter of energy helps soften the impact. Stephen Brown, deputy chief North America economist at Capital Economics, wrote in a note this week that…
-
Q4 signaled investor rotation “from gold to black gold,” BofA says
Investor positioning began shifting in the fourth quarter as money managers rotated capital “from gold to black gold,” according to a note released Tuesday by Bank of America strategist Savita Subramanian. Subramanian pointed out that investors had already started increasing exposure to Energy before the latest U.S.-Israel strikes on Iran, with the subsequent retaliatory attacks…
-
Oil demand destruction likely only at around $155/bbl, Bernstein says
Oil prices would have to climb significantly above current levels before triggering a meaningful drop in demand, according to analysis from Bernstein. Analyst Irene Himona said that “in today’s money we would need $155/bbl as the FY26 annual average, to reach the same 5.2% oil burden” experienced in 2007, a level historically associated with high…
-
Foresight Autonomous Holdings : Eye-Net Collision Prevention Technology Shows Positive Results in Bordeaux Transit Trial
Foresight Autonomous Holdings Ltd. (NASDAQ:FRSX) said its majority-owned subsidiary Eye-Net Mobile Ltd. has successfully completed a large-scale live pilot of a smart mobility safety project in Bordeaux, France, conducted in collaboration with Renault Group, Orange S.A., and other partners. The project, known as SafeCycloMove, tested Eye-Net’s collision-prevention technology in a real-world public transportation environment involving…
-
Acurx Pharmaceuticals Reports Stronger Cash Position and Clinical Progress in Q4 2025
Acurx Pharmaceuticals (NASDAQ:ACXP) reported fourth-quarter and full-year 2025 results highlighting a stronger cash position and continued progress in the development of its lead antibiotic candidate, ibezapolstat, for the treatment of Clostridioides difficile infection (C. difficile). The company said its cash balance more than doubled year over year, reaching $7.6 million as of December 31, 2025,…
-
Aditxt Acquires Ignite Proteomics to Expand Precision Oncology Capabilities
Aditxt Inc. (NASDAQ:ADTX) announced it has acquired Ignite Proteomics LLC, a precision oncology company specializing in functional proteomics technology used to guide cancer treatment decisions, according to a company press release. The deal assigns Ignite a stated value of $36 million, with Aditxt issuing 36,000 shares of newly created Series A-2 Convertible Preferred Stock as…
-
Innovation Beverage Prices $6M Public Offering at $1.75 Per Unit
Innovation Beverage Group Limited (NASDAQ:IBG) announced the pricing of a public offering expected to raise approximately $6 million in gross proceeds before fees and expenses, according to a company press release. The offering includes 3,428,569 units priced at $1.75 each. Each unit consists of one ordinary share or one pre-funded warrant, along with one Series…
-
Immutep Shares Collapse After Lung Cancer Trial Halted for Futility
Immutep Limited (NASDAQ:IMMP) shares plunged roughly 80% on Friday after the biotechnology company announced it would discontinue its Phase III TACTI-004 clinical trial following a futility review. The Independent Data Monitoring Committee (IDMC) recommended ending the study, which was evaluating eftilagimod alfa (“efti”) as a treatment for patients with first-line non-small cell lung cancer. After…
-
DevvStream Cuts $5.9M in Debt Through Equity Conversions and New Financing Support
DevvStream Corp. (NASDAQ:DEVS) said Thursday it has completed a series of transactions that reduce its outstanding debt by approximately $5.9 million, according to a company press release. The move comes as the company works to address liquidity pressures, with its current ratio standing at 0.12 for the trailing twelve months ending Q1 2026. As part…